Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
MABWELL-B (02493.HK) 9MW5211 Injection Clinical Trial Application Approved by NMPA
Recommend 1 Positive 2 Negative 0 |
||||
|
||||
|
MABWELL-B (02493.HK) announced that it has received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration (NMPA). The clinical trial application for 9MW5211 injection for the indication of inflammatory bowel disease (IBD) has been approved. In addition, its clinical trial application in the United States for the IBD indication has been cleared by the U.S. Food and Drug Administration (FDA). Clinical trial applications for multiple sclerosis (MS) and other indications have been accepted by the NMPA. The company is also actively advancing clinical trial applications for other indications. (sl/u) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
